From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: Treating “Problematic” Cases of Polycythemia Vera
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: Treating a Young Patient With Newly Diagnosed ALL
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: What is the prognosis for symptomatic, bulky FL...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: How would you use molecular diagnostic tests to...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: How would you treat MDS that has not...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
Studies Examine Link Between Ibrutinib and Atrial Fibrillation in Patients With Leukemia and Lymphoma
Though drug ibrutinib has been linked to the development of atrial fibrillation (AF) and atrial flutter (AFl), with an observed incidence of AF among...
A Look at Patient Outcomes in Overlapping Multiple Myeloma and Chronic Lymphocytic Leukemia
Though multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) have overlapping epidemiologic features and originate from mature B cells, the simultaneous occurrence of both...
Improving Risk Stratification in Standard-Risk Myeloma Patients: Age, Bone Marrow Involvement Independently Predict Survival
Though the field of multiple myeloma (MM) has seen many advances in treatment in the past two years – including three new drug approvals...
Adolescents and Minority Groups Underrepresented in Cancer Clinical Trials
Adolescent and young adult (AYA) patients, defined as those between the ages of 15 and 29 years, and non-white patients are often under-represented in...
Current Issue
January 2019 Annual Meeting Edition
This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.
